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GPER mediates the angiocrine actions
induced by IGF1 through the HIF-1α/VEGF
pathway in the breast tumor
microenvironment
Ernestina M. De Francesco1,2*, Andrew H. Sims3, Marcello Maggiolini1, Federica Sotgia4, Michael P. Lisanti4
and Robert B. Clarke2*
Abstract
Background: The G protein estrogen receptor GPER/GPR30 mediates estrogen action in breast cancer cells as well
as in breast cancer-associated fibroblasts (CAFs), which are key components of microenvironment driving tumor
progression. GPER is a transcriptional target of hypoxia inducible factor 1 alpha (HIF-1α) and activates VEGF
expression and angiogenesis in hypoxic breast tumor microenvironment. Furthermore, IGF1/IGF1R signaling, which
has angiogenic effects, has been shown to activate GPER in breast cancer cells.
Methods: We analyzed gene expression data from published studies representing almost 5000 breast cancer
patients to investigate whether GPER and IGF1 signaling establish an angiocrine gene signature in breast cancer
patients. Next, we used GPER-positive but estrogen receptor (ER)-negative primary CAF cells derived from patient
breast tumours and SKBR3 breast cancer cells to investigate the role of GPER in the regulation of VEGF expression
and angiogenesis triggered by IGF1. We performed gene expression and promoter studies, western blotting and
immunofluorescence analysis, gene silencing strategies and endothelial tube formation assays to evaluate the
involvement of the HIF-1α/GPER/VEGF signaling in the biological responses to IGF1.
Results: We first determined that GPER is co-expressed with IGF1R and with the vessel marker CD34 in human
breast tumors (n = 4972). Next, we determined that IGF1/IGF1R signaling engages the ERK1/2 and AKT transduction
pathways to induce the expression of HIF-1α and its targets GPER and VEGF. We found that a functional
cooperation between HIF-1α and GPER is essential for the transcriptional activation of VEGF induced by IGF1.
Finally, using conditioned medium from CAFs and SKBR3 cells stimulated with IGF1, we established that HIF-1α and
GPER are both required for VEGF-induced human vascular endothelial cell tube formation.
Conclusions: These findings shed new light on the essential role played by GPER in IGF1/IGF1R signaling that
induces breast tumor angiogenesis. Targeting the multifaceted interactions between cancer cells and tumor
microenvironment involving both GPCRs and growth factor receptors has potential in future combination
anticancer therapies.
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Background
It has become increasingly recognized that the neoplastic
evolution from a locally growing mass into a disseminat-
ing and aggressive metastatic disease is strongly influenced
by biological events occurring in the surrounding reactive
tumor stroma, which includes fibroblasts, endothelial cells
and macrophages [1]. In particular, cancer-associated fi-
broblasts (CAFs) at the interface with cancer cells coord-
inate an executive biochemical program that enhances
tumor progression mainly by facilitating cancer cell prolif-
eration, migration, invasion and angiogenesis [2, 3]. In this
regard, paracrine factors secreted by CAFs have been
shown to trigger the formation of new blood vessels
within solid tumors, thus allowing cancer cells adaptation
to the local hypoxic microenvironment toward the acqui-
sition of malignant features [4–6]. Given the evidence that
tumor angiogenesis drives cancer aggressiveness and re-
fractoriness to treatments, it is necessary to better charac-
terise the molecular mechanisms involved in order to
identify relevant targets of pharmacological intervention
[7]. The vascular endothelial growth factor A (VEGF-A,
also referred to as VEGF), the most notable pro-
angiogenic factor, plays a key role in the generation of new
blood vessel networks which provide oxygen and nutrients
supply [8]. In the tumor microenvironment, the regulation
of VEGF expression is mediated by the transcription fac-
tor hypoxia inducible factor-1 (HIF-1) and stimulated by
low oxygen, hormones, cytokines and growth factors [8,
9]. Insulin-like growth factor 1 (IGF1) plays a pivotal role
in the progression of diverse malignancies [10, 11], and
has been shown to promote tumor angiogenesis by acti-
vating the HIF-1α/VEGF signaling pathway [12–16]. We
have recently demonstrated that the G protein estrogen
receptor (GPER) is a novel target gene of HIF-1α, involved
in the regulation of VEGF in hypoxic breast tumor micro-
environment [17–19]. Interestingly, GPER expression has
been associated with poor clinical-pathological features in
breast, endometrial and ovarian cancer patients [20–22].
GPER expression is correlated with VEGF production [23]
and has been causally linked to tamoxifen resistance in
breast cancer [24, 25]. We have previously demonstrated
that IGF1 regulates GPER expression and function in
mesothelioma and lung cancer cells [26], as well as in es-
trogen receptor (ER)-positive breast cancer cells [27], pro-
viding evidence that GPER may act as a further relevant
contributor to the biological responses triggered by the
IGF1 signaling system. In the present study, we demon-
strate the strong correlation of GPER to angiocrine gene
expression in breast tumours from several large cohorts
totalling 4972 patients and evaluate the role of GPER in
the regulation of VEGF expression and angiogenesis in
GPER-positive but ER-negative primary CAFs obtained
from breast tumour patients and SKBR3 breast cancer
cells. We identify the molecular mechanisms through
which the IGF1/IGF1R axis induces HIF-1α and GPER ex-
pression toward the stimulation of VEGF and human vas-
cular endothelial cell tube formation.
Methods
Reagents
Insulin-like growth factor 1 (IGF1) was purchased from
Sigma Aldrich Co Limited. Tyrphostin. AG1024 (AG) and
PD98059 (PD) were purchased from Santa Cruz Biotech-
nology. Wortmannin (WM) was acquired from Life Tech-
nologies Ltd. SU5416 was supplied by Generon Ltd.
Human VEGF was purchased from Peprotech EC: Lim-
ited. All compounds were solubilized in DMSO, except
for IGF1 and VEGF, which were dissolved in water.
Cell cultures
The SKBR3 breast cancer cells, obtained from ATCC,
were maintained in DMEM (Sigma-Aldrich) with phenol
red, supplemented with 10% fetal bovine serum (FBS),
1% penicillin/streptomycin and 1% Glutamax (Life Tech-
nologies). Human umbilical vein endothelial cells
(HUVECs) were obtained from Sigma-Aldrich Co Lim-
ited and cultured in endothelial growth medium (EGM)
(Lonza, Basel, Switzerland), supplemented with 5% FBS
(Lonza). MCF7 breast and LnCAP prostate cancer cells,
both obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA), were grown in DMEM
and RPMI-1640 respectively, supplemented with 10%
FBS, 1% penicillin/streptomycin and 1% Glutamax (Life
Technologies). All cell lines were grown in a 37 ° C incu-
bator with 5% CO2. Cells were switched to medium
without serum the day before experiments.
Isolation, cultivation and characterization of CAFs
To isolate cancer-associated fibroblasts (CAFs), signed in-
formed consent from patients and institutional review
board (IRB) approval were obtained. CAFs were isolated,
cultivated and characterized as previously described [18].
Briefly, bioptic fragments from invasive mammary ductal
carcinoma patients undergoing mastectomy were cut into
small pieces (1 to 2 mm diameter), placed in digestion solu-
tion (400 IU collagenase, 100 IU hyaluronidase and 10%
FBS, containing antibiotics and antimycotics solution) and
incubated overnight at 37 °C. Cells were then separated by
differential centrifugation at 90 × g for 2 minutes. The
supernatant containing fibroblasts were centrifuged at
485 × g for 8 minutes, the pellet obtained was suspended in
fibroblasts growth medium (Medium 199 and Ham’s F12
mixed 1:1 and supplemented with 10% FBS and 1% penicil-
lin) and cultured at 37 °C, 5% CO2. In each patient, a sec-
ond population of fibroblasts was isolated from a
noncancerous breast tissue at least 2 cm from the outer
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tumor margin. CAFs and fibroblasts were then expanded
into two 15-cm Petri dishes and stored as cells passaged for
two to three population doublings within a total 7 to 10 days
after tissue dissociation. Primary cells cultures of breast fi-
broblasts were characterized by immunofluorescence. In
particular, cells were incubated with anti-vimentin (V9) and
anti-cytokeratin 14 (LL001), obtained from Santa Cruz Bio-
technology, Dallas, TX, USA. In order to assess fibroblast
activation, we used anti-fibroblast activated protein α
(FAPα) antibody (H-56) (Santa Cruz Biotechnology).
Generation of stable hypoxia response element (HRE)-driven
reporter SKBR3 cell line
To generate a stable HRE reporter cell line (SKBR3-HRE),
which contains a luciferase gene under the transcriptional
control of multiple tandemly arrayed copies of HRE se-
quence, the pGreenFire™ Pathway Reporter Constructs
packaged in pseudotyped viral particles (Stratech Scientific
Ltd) was used. Briefly, 50,000 SKBR3 cells were seeded in
24-well plate in regular growth medium for 24 h. When
50–70% confluent, medium was combined with Polybrene,
before the addition of the lentiviral particles. After 72 hours,
cells were subjected to selection with 2 μg/mL puromycin
(Life Technologies) for 20 days. The puromycin-resistant
clones were isolated and screened by measuring their basal
and inducible (obtained by exposure to hypoxia, 2% O2) lu-
ciferase activity, as described below.
Gene reporter assays
The 2.6 kb VEGF promoter-luciferase construct containing
full-length VEGF promoter sequence (22,361 to +298 bp
relative to the transcription start site) used in luciferase as-
says was a kind gift from Dr. P. Soumitro (Harvard Medical
School, Boston, MA, USA). The GPER promoter-luciferase
construct (pGPER 2.9 kb) was obtained as previously de-
scribed [17]. SKBR3 (1 × 105) were plated into 24-well
dishes with 500 μL/well culture medium containing 10%
FBS. Transfections were performed using X-treme GENE 9
DNA transfection reagent as recommended by the manu-
facturer (Roche Diagnostics, Basel, Switzerland, distributed
by Scientific Laboratory Supplies Ltd), with a mixture con-
taining 0.5 μg of reporter plasmid and 10 ng of pRL-TK.
After 24 h, cells were treated with IGF1, as indicated. For
co-transfection experiments, cells were previously trans-
fected with control shRNA, shHIF-1α or shGPER using X-
treme GENE 9 DNA transfection reagent (Roche Diagnos-
tics, distributed by Scientific Laboratory Supplies Ltd). A
mixture containing 0.5 μg of reporter plasmid and 10 ng of
pRL-TK was then transfected by using X-treme GENE 9
DNA transfection reagent. After 8 hours, cells were treated
for 18 hours with IGF1 in serum-free medium. Luciferase
activity was measured with the Dual Luciferase Kit (Pro-
mega, Madison, WI, USA) normalized to the internal trans-
fection control provided by Renilla luciferase activity. The
normalized relative light unit values were expressed as the
average fold induction of luciferase activity relative to the
vehicle-treated cells, whose luciferase activity was set as
100%.
Gene expression studies
Total RNA was extracted from cell cultures using the
TRIzol commercial kit (Life Technologies) according to
the manufacturer’s protocol. RNA was quantified spec-
trophotometrically and quality was checked by electro-
phoresis through agarose gels stained with ethidium
bromide. Only samples that were not degraded and
showed clear 18 and 28 S bands under UV light were
used for RT-PCR. Total cDNA was synthesized from the
RNA by reverse transcription as previously described
[18]. The expression of selected genes was quantified by
real-time PCR using Step One™ sequence detection
system (Applied Biosystems, Foster City, CA, USA), fol-
lowing the manufacturer’s instructions. Gene-specific
primers were designed using Primer Express version 2.0
software (Applied Biosystems) and are as follows: HIF-
1α Fwd: 5’-TGCATCTCCATCTTCTACCCAAGT-3’ and
Rev: 5’-CCGACTGTGAGTGCCACTGT-3’; VEGF Fwd:
5’- TGCAGATTATGCGGATCAAACC-3’ and Rev: 5’-
TGCATTCACATTTGTTGTGCTGTAG-3’; GPER Fwd:
5′-CCTGGACGAGCAGTATTACGATATC-3′ and Rev
5′-TGCTGTACATGTTGATCTG-3′; 18S Fwd: 5’- GG
CGTCCCCCAACTTCTTA -3’ and Rev: 5’- GGGCAT-
CACAGACCTGTTATT -3’. Assays were performed in
triplicate and the results were normalized for 18S ex-
pression and then calculated as fold induction of RNA
expression.
Western blot analysis
CAFs and SKBR3 cells were processed according to the
previously described protocol [18] to obtain protein lysate
that was electrophoresed through a reducing SDS/10% (w/
v) polyacrylamide gel, electroblotted onto a nitrocellulose
membrane and probed with primary antibodies against
HIF-1α (R&D Systems, Europe Ltd), GPER (N-15), phos-
phorylated extracellular signal-regulated kinase (ERK) 1/2
(E-4), ERK2 (C-14), β-actin (C2), all purchased from Santa
Cruz Biotechnology, pAKT (Ser 473) and AKT, which were
obtained from Cell Signaling, ERα (Dako, Glostrup,
Denmark), ERβ and IGF1R (Millipore). Proteins were de-
tected by horseradish peroxidase-linked secondary anti-
bodies (Cell Signaling) and revealed using the West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific,
Waltham, MA, USA).
Gene silencing experiments
Cells were plated onto 10-cm dishes and transfected
using X-treme GENE 9 DNA Transfection Reagent
(Roche Diagnostics, distributed by Scientific Laboratory
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Supplies Ltd) for 24 hours before treatments with a con-
trol shRNA, shHIF-1α, shGPER. The HIF-1α shRNA
and the respective control plasmid were purchased from
SABioscience Corporation. The silencing of GPER ex-
pression was obtained by the construct that we have pre-
viously described and used [28].
Immunofluorescence assay
Fifty percent confluent cultured CAFs and SKBR3 cells
grown on coverslips were serum deprived and then
treated for 8 hours with IGF1 alone and in combination
with AG1024, PD98059 and Wortmannin, as indicated.
Where required, cells previously transfected for 24 hours
with shHIF-1α or shGPER and respective negative con-
trol plasmids (as described above) and then treated for
8 hours with IGFI. Then cells were fixed in 4% parafor-
maldehyde, permeabilized with 0.2% Triton X-100,
washed three times with PBS and incubated overnight
with a mouse primary antibody against VEGF (C-1)
(Santa Cruz Biotechnology). After incubation, the slides
were extensively washed with PBS, probed with donkey
anti-mouse IgG-FITC (1:300; purchased from Alexa
Fluor, Life Technologies) and 4′,6-diamidino-2-phenylin-
dole dihydrochloride (DAPI) (Sigma-Aldrich Co Lim-
ited) and then imaged on a fluorescence microscope.
Conditioned medium
CAFs and SKBR3 cells were cultured in regular growth
medium, then cells were washed twice with PBS and
transfected for 24 hours in serum-free medium with
shHIF-1α, shGPER or control shRNA using X-treme
GENE 9 DNA Transfection Reagent (Roche Diagnostics,
distributed by Scientific Laboratory Supplies Ltd). Cells
were treated for 8 hours with IGF1, culture medium was
then replaced for additional 12 hours with medium with-
out serum. Thereafter, the supernatants were collected,
centrifuged at 3500 rpm for 5 minutes to remove cell deb-
ris and used as conditioned medium in HUVECs.
Tube formation assay
The day before the experiment, confluent HUVECs
were starved overnight at 37 °C in serum-free medium.
Growth factor-reduced Matrigel® (R&D Systems Europe
Ltd) was thawed overnight at 4 °C on ice, plated on the
bottom of pre-chilled 96-well plates and left at 37 °C
for 1 hour for gelification. Starved HUVECs were col-
lected by enzymatic detachment (0.25% trypsin-EDTA
solution, Life Technologies), counted and resuspended
in conditioned medium from CAFs or SKBR3 cells.
Then, 10,000 cells/well were seeded on Matrigel and in-
cubated at 37 °C. Tube formation was observed starting
from 4 hours after cell seeding and quantified by using
the software NIH ImageJ (National Institutes of Health
(NIH), Bethesda, MD, USA).
Gene expression signature in breast cancer patients
Gene expression levels of GPER and IGF1 signaling-
related genes were retrieved from the Molecular Tax-
onomy of Breast Cancer International Consortium
(METABRIC) dataset [29] and from integrating 17 Affy-
metrix gene expression datasets as previously described
[30]. Gene expression data from both Affymetrix and
METABRIC studies were representative of both ER-
positive (+) and ER-negative (-) breast tumours. Similarly,
Affymetrix gene expression data from three breast cancer
cell line panel studies were integrated as described
previously [30].
Statistical analysis
Statistical analysis was performed using t tests and
Spearman correlations. p < 0.05 was considered statisti-
cally significant.
Results
GPER and IGF1R define an angiocrine signature in breast
tumor patients
In order to evaluate whether GPER is involved in the an-
giogenic actions elicited by the IGF1 system in breast can-
cer, we analyzed gene expression from 17 published
Affymetrix microarray tumor gene expression datasets of
2999 breast cancer patients [30] and METABRIC [29], a
second independent dataset of 1973 breast tumor samples
analysed for gene expression using Illumina BeadChips.
Our analysis considered a panel of genes implicated in
angiogenesis and correlated them with the expression of
GPER. In both datasets, a strong, positive correlation in
expression was found between GPER and IGF1R, and be-
tween GPER and the microvessel density marker CD34
[31] (Fig. 1), indicating that IGF1R and GPER may be in-
volved in angiocrine regulation of the breast tumor micro-
environment. In contrast, IGF1, VEGFA and VEGFB were
not significantly correlated with GPER expression, and a
negative correlation was detected between the expression
of GPER and HIF-1α (Fig. 1). These large, independent
patient datasets, comprising 4972 breast tumors, sug-
gested to us that GPER, IGF1/IGF1R signaling and blood
vessel density (CD34) are correlated, and that GPER and
IGF signaling may be linked to changes in the breast
tumor microenvironment.
IGF1 induces HIF-1α, GPER and VEGF expression to stimulate
angiocrine signaling by the breast tumour
microenvironment
Based on the above correlations, we investigated the
cross-talk between GPER and IGF1/IGF1R system in me-
diating tumor angiogenesis in vitro. To model the breast
tumor microenvironment, we used cancer-associated fi-
broblasts (CAFs) isolated from breast tumor patients (see
Methods), and in addition, the SKBR3 breast cancer cell
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line, which is classed as luminal by gene expression
analysis (Additional file 1: Figure S1A). This analysis of
unsupervised clustering of three integrated breast cell
line datasets showed a strong correlation between
IGF1R and GPER expression in the luminal cell lines
(Additional file 1: Figure S1B).
In addition, both CAFs and SKBR3 cells express GPER
and IGF1R, but not ERs (Additional file 2: Figure S2A),
thus allowing us to investigate the interactions between
GPER and the IGF1/IGF1R axis, without any contribution
and/or interference from ER signaling. In order to investi-
gate the angiocrine actions of IGF1 in breast tumour, first
a
b
d
e f
c
Fig. 1 GPER correlates with IGF1R and CD34 expression in breast tumor samples. Data showing angiocrine-related genes across the 17 study
integrated Affymetrix (a-c) and METABRIC (d-f) datasets of 2999 and 1973 breast cancer patients, respectively. In the heatmaps, ranked from left to
right GPER expression correlates with IGF1R and the angiogenic marker CD34. Colors are log2 mean-centered values; red indicates high, and green
indicates low. Tumours in which GPER is called ‘present’ (GPER+) using the MAS5 detection calls are indicated in grey. GPER G-protein estrogen re-
ceptor, HIF-1 hypoxia inducible factor-1, IGF1 insulin-like growth factor 1, VEGF vascular endothelial growth factor
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of all we asked whether IGF1 induces the expression of
VEGF and its transcriptional regulator HIF-1α in our ex-
perimental models. IGF1 upregulated the mRNA expres-
sion of HIF-1α and VEGF (Fig. 2a-b), as determined
performing RT-PCR experiments in both CAFs and
SKBR3 cells. Further corroborating these findings, IGF1
increased the luciferase activity of SKBR3 cells engineered
to stably express a hypoxia response element (HRE)-
driven reporter construct (SKBR3-HRE-luc) (Fig. 2c); in
addition, the transactivation of a VEGF promoter con-
struct (pVEGF) was observed in SKBR3 cells stimulated
with IGF1 (Fig. 2d). Next, we assessed whether GPER is
a
c
f g
h i
j
d e
b
Fig. 2 IGF1 induces the expression of HIF-1α, GPER and VEGF. mRNA expression of HIF-1α, GPER and VEGF in CAFs (a) and SKBR3 (b) cells treated
for 8 hours with 100 ng/mL, as evaluated by real-time PCR. Values are normalized to the 18S expression and shown as fold changes of mRNA
expression induced by IGF1 compared to cells treated with vehicle. Data are mean ± SEM of three independent experiments performed
in triplicate. c Evaluation of luciferase activity in SKBR3 cells infected with a HRE reporter construct (SKBR3-HRE-luc) and treated for
18 hours with IGF1 (100 ng/mL). The luciferase activities were normalized to the protein content, evaluated in parallel plate by SRB
(sulforhodamine B) assay. The transactivation of a VEGF (pVEGF) (d) and a GPER (pGPER) (e) promoter construct is observed in SKBR3
cells treated with 100 ng/mL IGF1 for 18 hours. Luciferase activity was normalized to the internal transfection control. Results are
expressed as the % change of normalized RLU values relative to vehicle-treated cells. Data shown are the mean ± SEM of two independent experiments
performed in triplicate. Representative immunoblots showing the increase of HIF-1α and GPER protein expression in CAFs (f) and SKBR3 cells (g) treated
with 100 ng/mL IGF1 for 8 hours. The upregulation of GPER protein expression observed treating CAFs (h) and SKBR3 cells (i) for 8 hours with 100 ng/mL
IGF1 is abrogated by silencing HIF-1α. β-actin serves as loading control. j The transactivation of a GPER promoter construct (pGPER)
detected in SKBR3 cells treated with 100 ng/mL IGF1 for 18 hours is abrogated by HIF-1α silencing. (*), (○), p < 0.05; (**), (○○), (●●) p
< 0.01; (***), (●●●) p < 0.001. CAFs cancer-associated fibroblasts, GPER G-protein estrogen receptor, HIF-1 hypoxia inducible factor-1, IGF1
insulin-like growth factor 1, VEGF vascular endothelial growth factor
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involved in the aforementioned stimulatory responses in-
duced by IGF1. In both CAFs and SKBR3 cells, IGF1 in-
duced the upregulation of GPER mRNA levels (Fig. 2a-b)
and transactivated a GPER promoter construct (pGPER)
(Fig. 2e). At the protein level, IGF1 induced HIF-1α and
GPER expression in a time-dependent manner, as deter-
mined by western blotting experiments performed in both
CAFs and SKBR3 cells (Fig. 2f-g and Additional file 2:
Figure S2b-c). Furthermore, the upregulation of GPER
protein expression (Fig. 2h-i and Additional file 2: Figure
S2 D-E) and the transactivation of a GPER promoter con-
struct (Fig. 2j) induced by IGF1 were prevented in the
presence of HIF-1α knockdown (Additional file 3: Figure
S3 A-C), indicating that GPER is induced by IGF1 via
HIF-1α transcriptional activity.
Altogether, these findings suggest that HIF-1α and its
transcriptional targets GPER and VEGF are triggered by
IGF1 both in breast tumor microenvironmentally de-
rived CAFs and in luminal breast cancer cells.
Molecular mechanisms of the angiocrine activity of IGF1
Previously, ERK1/2 and AKT signaling cascades have
emerged as pivotal transduction mediators involved in
IGF1-induced and HIF-1-dependent responses in cancer
cells [32, 33]. On the basis of these observations, we de-
termined that the upregulation of HIF-1α and GPER
protein expression induced by IGF1 was repressed in the
presence of the IGF1R tyrosine kinase inhibitor AG1024
(AG), the MEK inhibitor PD98059 (PD) as well as the
PI3K inhibitor Wortmannin (WM) (Fig. 3a-b and
Additional file 4: Figure S4 A,D). Accordingly, the lucif-
erase activity of SKBR3 cells engineered to stably express
a hypoxia response element (HRE)-driven reporter con-
struct (SKBR3-HRE-luc) and the transactivation of a
GPER promoter construct observed upon treatment with
IGF1 were prevented by AG, PD and WM (Fig. 3h-i). Of
note, these three pharmacological inhibitors were also
able to block the increase of VEGF protein expression
together with the transactivation of a VEGF promoter
construct induced by IGF1, as demonstrated by im-
munofluorescence experiments and luciferase assays re-
spectively (Fig. 3g, j and Additional file 5: Figure S5).
Corroborating these findings, in CAFs and SKBR3 cells
stimulated with IGF1 the activation of ERK1/2 and AKT
was prevented by AG, PD and WM (Fig. 3c-f and
Additional file 4: Figure S4 B,C,E,F). Taken together
these findings suggest that IGF1/IGF1R axis engages
ERK1/2 and AKT signaling to trigger the activation of
HIF-1α/GPER/VEGF transduction pathway in breast
tumor microenvironment.
Our previous investigations have evidenced the func-
tional cooperation between HIF-1α and GPER in the
regulation of VEGF expression and angiogenesis in hyp-
oxic breast tumor microenvironment [18]. Thus, we
sought to address whether both HIF-1α and GPER are
required for the regulation of VEGF expression induced
by IGF1. In CAFs and SKBR3 cells, IGF1 failed to in-
crease VEGF protein expression (Fig. 4a and Additional
file 6: Figure S6 A-B) and activate a VEGF promoter
construct (Fig. 4b) in the presence of HIF-1α knockdown
(Additional file 3: Figure S3 D-E). Interestingly, gene si-
lencing experiments demonstrated that also GPER is re-
quired for the upregulation of VEGF protein expression
(Fig. 4c, Additional file 3: Figure S3F and Additional file
6: Figure S6 C-D) and the transactivation of a VEGF pro-
moter construct induced by IGF1 (Fig. 4d and
Additional file 3: Figure S3 G). Collectively, these data
provide evidence on the molecular mechanisms acti-
vated by IGF1 through GPER toward the regulation of
VEGF expression in breast cancer cells.
IGF1 regulates HIF-1α/GPER signaling to trigger VEGF-
mediated endothelial tube formation
On the basis of the findings above that indicate that a
functional interplay between HIF-1α and GPER regulates
the expression of the key angiogenic mediator VEGF, we
next evaluated the contribution of HIF-1α/GPER signal-
ing to the stimulatory response induced by IGF1 in
breast tumor microenvironment. Conditioned medium
obtained from CAFs and SKBR3 cells was collected and
used in HUVEC tube formation assay in Matrigel. As
shown in Fig. 5, a complex and ramified network of tu-
bules was detected in HUVECs cultured in conditioned
medium from CAFs treated with IGF1 (panel A), while
this effect was no longer evident in the presence of HIF-
1α and GPER silencing (panels B-C and Additional file
3: Figure S3 H-I). However, a complete rescue of tubulo-
genesis was observed when VEGF was added to the con-
ditioned medium collected from GPER-silenced and
IGF1-treated CAFs (Fig. 5c). These data were quantified
in Fig. 5d and Additional file 7: Figure S7 A-B. Analo-
gous results were obtained performing tube formation
assay using HUVECs cultured with conditioned medium
collected from SKBR3 cells (Additional file 8: Figure S8).
In addition, the efficiency of endothelial tube formation
was significantly reduced when the VEGFR2 inhibitor
SU5416 was added to the conditioned medium obtained
from CAFs (Fig. 6a-b and Additional file 7: Figure S7 C-
D) and SKBR3 cells (Additional file 9: Figure S9) treated
with IGF1. Altogether, these results establish that HIF-
1α/GPER signaling is required downstream of IGF1 for
VEGF-mediated angiogenesis in the breast tumor
microenvironment.
Discussion
In the current study, we investigated the role of GPER in
the regulation of VEGF expression and tumor angiogenesis
induced by IGF1. We establish in primary patient-derived
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breast CAFs, and in luminal breast cancer cells that
IGF1 triggers the expression of VEGF and its tran-
scriptional regulators HIF-1α and GPER, through the
ERK1/2 and AKT transduction pathways. In addition,
we provide evidence that both HIF-1α and GPER
contribute to the regulation of VEGF stimulated by
IGF1. In biological assays, we showed that IGF1 re-
quires both HIF-1α and GPER to induce VEGF-
mediated endothelial tube formation, as evidenced by
HUVECs cultured with conditioned medium obtained
from CAFs and breast cancer cells treated with IGF1.
Interestingly, in human breast tumor samples, GPER
expression correlates with IGF1R and with the vessel
marker CD34, corroborating the engagement of GPER
and IGF1 system in breast tumor angiogenesis in
breast tumor microenvironment.
These findings are in accordance with previous evi-
dence obtained both in vitro and in vivo indicating that
a
c
e
h
b g
d
f
i
j
Fig. 3 ERK1/2 and AKT signaling pathways are involved in the upregulation of VEGF expression induced by IGF1. The upregulation of HIF-1α and
GPER protein expression observed treating CAFs (a) and SKBR3 cells (b) with 100 ng/mL IGF1 for 8 hours is abolished in the presence of 10 μM
IGF1R inhibitor AG1024 (AG), 10 μM MEK inhibitor PD98059 (PD) and 100 nM PI3K inhibitor Wortmannin (WM). The activation of ERK1/2 and AKT
(Ser 473) is prevented in CAFs (c, e) and SKBR3 cells (d, f) treated for 60 minutes with 100 ng/mL IGF1, alone and in combination with AG
(10 μM), PD (10 μM) and WM (100 nM). ERK2, AKT and β-actin serve as loading control, as indicated. g VEGF protein expression in CAFs treated
with 100 ng/mL IGF1 for 8 hours, alone and in combination with AG (10 μM), PD (10 μM) and WM (100 nM), as evidenced by immunfluoerscence experi-
ment. VEGF accumulation is shown by the green signal, nuclei are stained by DAPI (blue signal), bar scale 100 μM. Results shown are representative of two
independent experiments. Evaluation of luciferase activity in SKBR3 cells infected with a HRE reporter construct (SKBR3-HRE-luc) (h), and in SKBR3 cells
transiently transfected with a GPER (pGPER) (i) or a VEGF (pVEGF) promoter construct (j) and treated with 100 ng/mL IGF1 for 18 h in the presence of AG,
PD and WM. Luciferase activity was normalized to the internal transfection control. Results are expressed as the % change of normalized RLU values relative
to vehicle-treated cells. Each data point represents the mean ± SEM of two independent experiments performed in triplicate. (**) p< 0.01; (***) p< 0.001.
CAFs cancer-associated fibroblasts, GPER G-protein estrogen receptor, HIF-1 hypoxia inducible factor-1, IGF1 insulin-like growth factor 1
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IGF1 triggers VEGF-mediated neovascularization in
breast, endometrial, head and neck, lung, colon cancer
and sarcoma cells [13–16, 32, 34].
In this regard, the stimulatory action elicited by IGF1
has been particularly described for estrogen receptor
(ER)-positive breast tumors, where a cross-talk between
a
b
c
d
Fig. 4 HIF-1α and GPER are involved in VEGF protein increase induced by IGF1. a Evaluation of VEGF protein expression by
immunofluorescence experiment in CAFs transfected for 24 hours with control shRNA (panels 1–4) or shHIF-1α (panels 5–8) and treated
with 100 ng/mL IGF1 for 8 hours, as indicated. b The transactivation of a VEGF (pVEGF) promoter plasmid observed in SKBR3 cells
treated with 100 ng/mL IGF1 for 18 hours is abrogated silencing the expression of HIF-1α. c Evaluation of VEGF protein expression by
immunofluorescence experiment in CAFs transfected for 24 hours with control shRNA (panels 1–4) or shGPER (panels 5–8) and treated
with 100 ng/mL IGF1 for 8 hours, as indicated. In immunofluorescence experiments, VEGF accumulation is evidenced by the green
signal, nuclei are stained by DAPI (blue signal), bar scale 100 μM. Images shown are representative of two independent experiments.
d The transactivation of a VEGF (pVEGF) promoter plasmid observed in SKBR3 cells treated with 100 ng/mL IGF1 for 18 hours is
abrogated silencing the expression of GPER. In luciferase assays, luciferase activity was normalized to the internal transfection control.
Results are expressed as the % change of normalized RLU values relative to vehicle-treated cells. Each data point represents the mean
± SEM of two independent experiments performed in triplicate. (*) p < 0.05, p < 0.01 (**). CAFs cancer-associated fibroblasts, GPER
G-protein estrogen receptor, HIF-1 hypoxia inducible factor-1, IGF1 insulin-like growth factor 1, VEGF vascular endothelial growth factor
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Fig. 5 (See legend on next page.)
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IGF1R and ER transduction pathways has been shown to
regulate critical biological responses like cancer cell pro-
liferation and migration [35–38]. In the present study
we used as model systems patient-tumor derived CAFs
and SKBR3 breast cancer cells, which allowed us to
characterize the IGF1/IGF1R action in ER-negative
breast cancer cell setting. It should be mentioned that a
36 kDa splice variant of ERα named ERα36 has been
shown to be expressed in SKBR3 cells [39], however our
data demonstrate that GPER knockdown in SKBR3 cells
abrogates the stimulatory responses to IGF1, thus indi-
cating that GPER is required for the stimulatory actions
induced by IGF1.
We found that the IGF1/IGF1R transduction pathway
through the involvement of ERK1/2 and AKT signaling
cascades triggers an angiogenic gene signature character-
ized by the increase of VEGF as well as its transcriptional
regulator HIF-1α. These data are well supported by previ-
ous evidence showing that the angiocrine action exerted
by IGF1 through IGF1R occurs through the activation of
HIF-1α/VEGF axis and the involvement of MAPK and
PI3K/AKT activity [32]. Importantly, stimuli other than
hypoxia like cytokines, chemokines, hormones and
growth factors have been reported to trigger HIF-1-
dependent responses through non-canonical mechanisms
[40]. In this regard, IGF1 has been shown to induce HIF-
1α protein synthesis at the translational level, without af-
fecting HIF-1 gene transcription or protein stability in
colon cancer cells [32] and an increase in HIF-1α mRNA
levels has been demonstrated after stimulation with IGF1
in several cells models [41–43]. Our results support these
studies, showing that IGF1/IGF1R axis triggers HIF-1 ex-
pression at the mRNA level leading to the transcription
of target genes.
(See figure on previous page.)
Fig. 5 HIF-1α and GPER are involved in the formation of endothelial tubes mediated by VEGF. Tube formation in HUVECs cultured in medium
collected from CAFs treated with vehicle or 100 ng/ml IGF1 for 18 hours; CAFs were transfected for 24 hours with control shRNA (a), shHIF-1α
(b) or shGPER (c) before adding treatments. c 10 ng/mL VEGF rescues tube formation in HUVECs cultured in conditioned medium from
GPER-silenced CAFs, which were treated with 100 ng/mL IGF1 for 18 hours. d Quantification of the number of tubes, observed in HUVECs,
as indicated. Data are representative of three independent experiments performed in triplicate. (***) p < 0.001. CAFs cancer-associated
fibroblasts, GPER G-protein estrogen receptor, HIF-1 hypoxia inducible factor-1, HUVECs human umbilical vein endothelial cells, IGF1 insulin-like growth
factor 1, VEGF vascular endothelial growth factor
Fig. 6 VEGF triggers endothelial tube formation via VEGFR2. a Endothelial tube formation is abrogated in HUVECs cultured for 4 hours
in medium collected from CAFs treated with 100 ng/mL IGF1 for 18 hours, in the presence of the VEGFR2 inhibitor SU5416 (1 μM).
b Quantification of the number of tubes observed in HUVECs, as indicated. Data are representative of three independent experiments
performed in triplicate. (***) p < 0.001. CAFs cancer-associated fibroblasts, HUVECs human umbilical vein endothelial cells, IGF1 insulin-like growth factor
1, VEGF vascular endothelial growth factor
De Francesco et al. Breast Cancer Research  (2017) 19:129 Page 11 of 14
Herein, we also show that IGF1 activates the HIF-1α-
dependent expression of GPER, required for the regulation
of VEGF in CAFs and breast cancer cells. GPER, which is
considered as a negative prognostic marker in breast cancer
[21], has been shown previously to be upregulated and/or
activated by a plethora of stimuli classically involved in HIF-
1 pathway, including hypoxia, EGF, IGF1, insulin and the
metals copper and zinc [2–27, 44–48]. In addition, in breast
cancer cells and CAFs as well as in a mouse model of breast
cancer, estrogenic GPER signaling has been shown to trigger
HIF-1α/VEGF pathway leading to angiogenesis and tumor
growth [48, 49]. In this context, data shown herein, indicat-
ing that GPER triggers VEGF expression and function, are
strengthened by previous investigations demonstrating that
GPER overexpression is associated with high VEGF produc-
tion rates in primary cell cultures derived from endometrial
cancer tissues [23]. Furthermore, our data regarding the in-
tegrated bioinformatic analysis of gene expression studies
from human breast tumor samples, evidence that GPER and
the IGF1/IGFIR system may be regarded as a peculiar angio-
crine signature, for their co-expression pattern with the
microvessel-density marker CD34 [31]. It should be men-
tioned that in our gene data, obtained from the integrated
bioinformatic analysis of human breast tumor samples,
IGF1 and VEGF are not positively correlated with the ex-
pression of GPER (Fig. 1). In addition, in contrast with our
in vitro findings, we detected a negative correlation between
HIF-1α and GPER gene expression in breast tumor samples.
Such discrepancies could be due to intrinsic limits of the
gene expression technique used, as well as to the relative
contribution of the diverse cellular components present in
the breast tumor samples, including macrophages, immune
cells and adipocytes. In addition, HIF-1α expression has
been shown to be tightly regulated by local oxygen levels,
which may be fluctuating in the tumor mass due to cycling
hypoxia; moreover, the fluctuation of HIF-1α expression in
response to oxygen or other stimuli are peculiarly and pri-
marily regulated at the protein level, as HIF-1α protein
stabilization occurs before mRNA transcription [50, 51]. It
should also be considered that the mechanisms and factors
involved in HIF-1α regulation are cell-type specific [52],
while the data shown in our bioinformatics analysis are rep-
resentative of the whole tumor tissue.
Nonetheless, our findings indicate that GPER and the
IGF1/IGF1R axis are co-expressed in human breast tumors,
suggesting that targeting IGF1R/GPER cross-talk might be
useful in halting the angiogenesis process, particularly in a
subset of breast cancer patients devoid of the classic ER. On
the basis of literature data and our present results, GPER
may be included among the transduction mediators in-
volved in neovascularization triggered by HIF-1α/VEGF sig-
naling axis in tumor microenvironment. The current study
corroborate the role of GPER in the complex process of
tumor angiogenesis induced by IGF1, supporting the idea
that the aberrant cross-talk between receptor tyrosine ki-
nases (RTKs)- and G-protein coupled receptors (GPCR)-
mediated signaling may converge on relevant biological re-
sponses driven by HIF-1 toward VEGF-dependent new
blood vessel formation.
Conclusions
Overall, our study provides novel evidence regarding the
angiocrine action elicited by IGF1 in breast cancer through
the activation of HIF-1α/VEGF signaling pathway, empha-
sizing the important role played by GPER in the modulation
of this relevant transduction axis. A better understanding of
the effects induced by IGF1 through GPER at the crossroad
between cancer, endothelial and stromal cells, may pave the
way for the therapeutic manipulation of the multiple signal-
ing networks that control tumor angiogenesis. Although
further validation of these results is required in additional
tumor models, our study suggests that reprogramming the
cross-talk between RTKs and GPCRs in the vascular niche
may represent a promising novel approach to control aber-
rant angiogenesis in cancer patients.
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